A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol

Julia Spierings, Anna van Rhenen, Paco Mw Welsing, Anne Ca Marijnissen, Ellen De Langhe, Nicoletta Del Papa, Daan Dierickx, Karina R Gheorghe, Joerg Henes, Roger Hesselstrand, Tessa Kerre, Per Ljungman, Arjan A van de Loosdrecht, Erik Waf Marijt, Miro Mayer, Marc Schmalzing, Roland Schroers, Vanessa Smith, Reinhard E Voll, Madelon C Vonk, Alexandre E Voskuyl, Jeska K de Vries-Bouwstra, Ulrich A Walker, Dirk M Wuttge, Jacob M van Laar, Julia Spierings, Anna van Rhenen, Paco Mw Welsing, Anne Ca Marijnissen, Ellen De Langhe, Nicoletta Del Papa, Daan Dierickx, Karina R Gheorghe, Joerg Henes, Roger Hesselstrand, Tessa Kerre, Per Ljungman, Arjan A van de Loosdrecht, Erik Waf Marijt, Miro Mayer, Marc Schmalzing, Roland Schroers, Vanessa Smith, Reinhard E Voll, Madelon C Vonk, Alexandre E Voskuyl, Jeska K de Vries-Bouwstra, Ulrich A Walker, Dirk M Wuttge, Jacob M van Laar

Abstract

Introduction: Systemic sclerosis (SSc) is a chronic, autoimmune connective tissue disease associated with high morbidity and mortality, especially in diffuse cutaneous SSc (dcSSc). Currently, there are several treatments available in early dcSSc that aim to change the disease course, including immunosuppressive agents and autologous haematopoietic stem cell transplantation (HSCT). HSCT has been adopted in international guidelines and is offered in current clinical care. However, optimal timing and patient selection for HSCT are still unclear. In particular, it is unclear whether HSCT should be positioned as upfront therapy or rescue treatment for patients refractory to immunosuppressive therapy. We hypothesise that upfront HSCT is superior and results in lower toxicity and lower long-term medical costs. Therefore, we propose this randomised trial aiming to determine the optimal treatment strategy for early dcSSc by comparing two strategies used in standard care: (1) upfront autologous HSCT versus (2) immunosuppressive therapy (intravenous cyclophosphamide pulse therapy followed by mycophenolate mofetil) with rescue HSCT in case of treatment failure.

Methods and analysis: The UPSIDE (UPfront autologous hematopoietic Stem cell transplantation vs Immunosuppressive medication in early DiffusE cutaneous systemic sclerosis) study is a multicentre, randomised, open-label, controlled trial. In total, 120 patients with early dcSSc will be randomised. The primary outcome is event-free survival at 2 years after randomisation. Secondary outcomes include serious adverse events, functional status and health-related quality of life. We will also evaluate changes in nailfold capillaroscopy pattern, pulmonary function, cardiac MR and high-resolution CT of the chest. Follow-up visits will be scheduled 3-monthly for 2 years and annually in the following 3 years.

Ethics and dissemination: The study was approved by the Dutch Central Committee on Research Concerning Human Subjects (NL72607.041.20). The results will be disseminated through patient associations and conventional scientific channels.

Trial registration numbers: NCT04464434; NL 8720.

Keywords: bone marrow transplantation; clinical trials; immunology; rheumatology; transplant medicine.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Study flow diagram. ATG, anti-thymocyte globulin; CYC, cyclophosphamide; HSCT, haematopoietic stem cell transplantation; MMF, mycophenolate mofetil.

References

    1. Denton CP, Khanna D. Systemic sclerosis. Lancet 2017;390:1685–99. 10.1016/S0140-6736(17)30933-9
    1. Elhai M, Meune C, Boubaya M, et al. . Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis 2017;76:1897–905. 10.1136/annrheumdis-2017-211448
    1. Tyndall AJ, Bannert B, Vonk M, et al. . Causes and risk factors for death in systemic sclerosis: a study from the EULAR scleroderma trials and research (EUSTAR) database. Ann Rheum Dis 2010;69:1809–15. 10.1136/ard.2009.114264
    1. Ioannidis JPA, Vlachoyiannopoulos PG, Haidich A-B, et al. . Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005;118:2–10. 10.1016/j.amjmed.2004.04.031
    1. Altman RD, Medsger TA, Bloch DA, et al. . Predictors of survival in systemic sclerosis (scleroderma). Arthritis & Rheumatism 1991;34:403–13. 10.1002/art.1780340405
    1. Bulpitt KJ, Clements PJ, Lachenbruch PA, et al. . Early undifferentiated connective tissue disease: III. outcome and prognostic indicators in early scleroderma (systemic sclerosis). Ann Intern Med 1993;118:602–9. 10.7326/0003-4819-118-8-199304150-00005
    1. Burt RK, Milanetti F. Hematopoietic stem cell transplantation for systemic sclerosis: history and current status. Curr Opin Rheumatol 2011;23:519–29. 10.1097/BOR.0b013e32834aa45f
    1. van Laar JM, Farge D, Sont JK, et al. . Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014;311:2490–8. 10.1001/jama.2014.6368
    1. Assassi S, Wang X, Chen G, et al. . Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures. Ann Rheum Dis 2019;78:1371–8. 10.1136/annrheumdis-2019-215770
    1. Eyraud A, Scouppe L, Barnetche T, et al. . Efficacy and safety of autologous haematopoietic stem cell transplantation in systemic sclerosis: a systematic review of the literature. Br J Dermatol 2018;178:650–8. 10.1111/bjd.15993
    1. Shouval R, Furie N, Raanani P, et al. . Autologous hematopoietic stem cell transplantation for systemic sclerosis: a systematic review and meta-analysis. Biol Blood Marrow Transplant 2018;24:937–44. 10.1016/j.bbmt.2018.01.020
    1. Host L, Nikpour M, Calderone A, et al. . Autologous stem cell transplantation in systemic sclerosis: a systematic review. Clin Exp Rheumatol 2017;35 Suppl 106:S198–207.
    1. Smith V, Scirè CA, Talarico R, et al. . Systemic sclerosis: state of the art on clinical practice guidelines. RMD Open 2019;4:e000782. 10.1136/rmdopen-2018-000782
    1. Kowal-Bielecka O, Fransen J, Avouac J, et al. . Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 2017;76:1327–39. 10.1136/annrheumdis-2016-209909
    1. van Bijnen S, de Vries-Bouwstra J, van den Ende CH, et al. . Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study. Ann Rheum Dis 2020;79:1084–9. 10.1136/annrheumdis-2020-217058
    1. Farge D, Burt RK, Oliveira M-C, et al. . Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for blood and marrow transplantation autoimmune diseases Working Party and collaborating partners. Bone Marrow Transplant 2017;52:1495–503. 10.1038/bmt.2017.56
    1. Carreras E, Mohty M, Kroger M. Hematopoietic Stem Cell Transplantation and Cellular Therapies. : The EBMT Handbook. Springer Nature Switzerland AG, 2019.
    1. Distler O, Assassi S, Cottin V, et al. . Predictors of progression in systemic sclerosis patients with interstitial lung disease. Eur Respir J 2020;55:1902026. 10.1183/13993003.02026-2019
    1. Andréasson K, Saxne T, Bergknut C, et al. . Prevalence and incidence of systemic sclerosis in southern Sweden: population-based data with case ascertainment using the 1980 Ara criteria and the proposed ACR-EULAR classification criteria. Ann Rheum Dis 2014;73:1788–92. 10.1136/annrheumdis-2013-203618
    1. Vonk MC, Broers B, Heijdra YF, et al. . Systemic sclerosis and its pulmonary complications in the Netherlands: an epidemiological study. Ann Rheum Dis 2009;68:961–5. 10.1136/ard.2008.091710
    1. Khanna D, Berrocal VJ, Giannini EH, et al. . The American College of rheumatology provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol 2016;68:299–311. 10.1002/art.39501
    1. Guideline for economic evaluations in healthcare. Available:
    1. Spierings J, van Rhijn– Brouwer FCC, de Bresser JM. Treatment decision-making in hematopoietic stem cell transplantation in patients with poor prognosis diffuse cutaneous systemic sclerosis. Rheumatology 2020;59:1226–32.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere